Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06628908 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
A Phase 3 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT06628908: Recruiting Phase 3 study of Diabetic Peripheral Neuropathic Pain, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06628908 is a Phase 3 study of Diabetic Peripheral Neuropathic Pain that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 1,100 participants, above the 280-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (293% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06628908, a Phase 3 study of Diabetic Peripheral Neuropathic Pain, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Conditions Studied
Interventions
- DRUG Suzetrigine
- DRUG Pregabalin
- DRUG Placebo (matched to SUZ)
- DRUG Placebo (matched to Pregabalin)
Study Locations (20)
California
- Neuro-Pain Medical Center - Fresno
- Long Beach Research Institute - Long Beach
- Angel City Research, Inc - Los Angeles
- Empire Clinical Research - Pomona
- Clinical Trials Research - Sacramento
- Velocity Clinical Research, San Bernardino - San Bernardino
- SCLA Management - Pain Management and Injury Relief - Thousand Oaks
- Diablo Clinical Research (DCR) - Walnut Creek
Florida
- Accel Research - Deland - DeLand
- AMR-Miami - Doral
- AMR Fort Myers (The Clinical Study Center) - Fort Myers
- Velocity Clinical Research - Hallandale Beach - Hallandale
- CNS Healthcare - Jacksonville - Jacksonville
Alabama
- Pinnacle Research Group, LLC - Anniston
- Synexus Clinical Research - Birmingham - Birmingham
- AMR Daphne, AL - Daphne
Arizona
- Synexus Clinical Research - Phoenix Central - Phoenix
- Scottsdale Clinical Trials - Scottsdale
Colorado
- Velocity Clinical Research - Denver - Englewood
District of Columbia
- Velocity Clinical Research - Washington DC - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2024-10-01 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 3 |
What NCT06628908 shows while recruiting
NCT06628908 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, above the 280-participant average among 7 other Diabetic Peripheral Neuropathic Pain trials with a reported enrollment target (293% higher).
The record links to 1 condition, with Diabetic Peripheral Neuropathic Pain appearing as the primary indexed condition, and to 4 interventions - of which Suzetrigine is the first listed.
NCT06628908 names 20 study sites across 6 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06628908 about?
NCT06628908 is a clinical study titled "Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy". The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
What is the current status of trial NCT06628908?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2024-10-01. Estimated completion is 2027-05-31.
What conditions does trial NCT06628908 study?
This clinical trial studies the following conditions: Diabetic Peripheral Neuropathic Pain.
What interventions are being tested in trial NCT06628908?
The interventions under investigation include: Suzetrigine (DRUG), Pregabalin (DRUG), Placebo (matched to SUZ) (DRUG), Placebo (matched to Pregabalin) (DRUG).
Who is sponsoring clinical trial NCT06628908?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06628908 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Peripheral Neuropathic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 3
-
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
ACTIVE NOT RECRUITING · Phase 3
-
MAD Study to Assess the Safety, Tolerability, PKs and Efficacy of YJ001 for Spray Use in Patients With DPNP
RECRUITING · Phase 1
-
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
RECRUITING · Phase 2
-
A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI